股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2024 - 2 3 号 江苏四环生物股份有限公司 5、公司第一大股东、实际控制人在公司股票交易异常波动期间未买卖公司 股票。 关于股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 江苏四环生物股份有限公司（以下简称"公司"）股票(证券简称：四环生 物，证券代码：000518)连续两个交易日（2024 年 5 月 8 日、2024 年 5 月 9 日） 收盘价涨幅偏离值累计超过 20%，根据深圳证券交易所的有关规定，属于股票交 易异常波动的情况。 二、公司关注并核实的相关情况 公司董事会针对股票交易异常波动对有关事项进行了核实，现将相关情况说 明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、近期公共传媒未报道可能或已经对本公司股票交易价格产生较大影响的 未公开重大信息。 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、公司、公司第一大股东、实际控制人不存在关于本公司的应披露而未披 露的重大事 ...

Financial Performance - The company's operating revenue for 2023 was ¥235,419,049.03, a decrease of 12.86% compared to ¥270,149,197.60 in 2022[19]. - The net profit attributable to shareholders for 2023 was -¥75,269,896.35, representing a decline of 54.26% from -¥48,792,770.94 in 2022[19]. - The net cash flow from operating activities decreased by 66.51% to ¥1,629,635.79 in 2023, down from ¥4,865,787.34 in 2022[19]. - The basic earnings per share for 2023 was -¥0.0731, a decrease of 54.22% compared to -¥0.0474 in 2022[19]. - Total assets at the end of 2023 were ¥660,975,034.49, down 10.45% from ¥738,078,462.55 at the end of 2022[19]. - The net assets attributable to shareholders decreased by 13.55% to ¥481,706,954.69 at the end of 2023, compared to ¥557,240,851.04 at the end of 2022[19]. - The company reported a weighted average return on equity of -14.49% for 2023, a decline from -8.39% in 2022[19]. - The company's revenue after deducting non-operating income was ¥229,609,696.11 in 2023, compared to ¥265,711,146.35 in 2022[20]. - The pharmaceutical business revenue was ¥225,964,755.62, reflecting a year-on-year decrease of 12.70% due to procurement policies[42]. - Total operating revenue for 2023 was ¥235,419,049.03, a decrease of 12.86% compared to ¥270,149,197.60 in 2022[44]. Cash Flow and Expenses - The net cash flow from operating activities showed fluctuations, with a positive cash flow of ¥3,050,580.73 in the first quarter, turning negative in the second quarter at -¥2,242,459.58, and returning to positive at ¥1,091,221.40 in the fourth quarter[24]. - Cash flow from operating activities was ¥1,629,635.79, a decline of 66.51% compared to the previous year[42]. - Total sales expenses decreased by 6.87% to ¥116,564,330.67, while R&D expenses decreased by 25.19% to ¥29,150,204.80[54]. - The company's operating costs for 2023 were ¥287,686,024.21, down from ¥311,217,662.78 in 2022, reflecting a reduction of 7.56%[200]. Inventory and Assets - The inventory accounted for 61.81% of total assets at the end of 2023, showing a 6.43% increase compared to the beginning of the year[59]. - As of December 31, 2023, the company's inventory assets had a book value of 439.52 million yuan, with a provision for inventory impairment of 30.99 million yuan[181]. - The company's total assets decreased slightly to CNY 660,975,034.49 in 2023 from CNY 738,078,462.55 in 2022, a decline of 10.5%[198]. - Current assets totaled CNY 509,380,002.54, down from CNY 564,819,858.63, indicating a reduction of about 9.8%[193]. - The company's cash and cash equivalents decreased to CNY 18,927,001.92 from CNY 28,180,123.46, representing a decline of approximately 32.8%[193]. Research and Development - The company holds 12 invention patents and 4 new drug certificates, indicating a strong R&D capability[41]. - R&D investment decreased by 25.19% from 38,968,076.78 CNY in 2022 to 29,150,204.80 CNY in 2023, accounting for 12.38% of operating revenue[56]. - The number of R&D personnel increased by 16.67% from 30 in 2022 to 35 in 2023, with a higher proportion of personnel holding bachelor's degrees[56]. - The company is developing a new eye drop formulation for cataract treatment, which is expected to create a new revenue growth point in the ophthalmic drug market[56]. Market and Industry Outlook - The pharmaceutical manufacturing industry is expected to continue growing due to increasing global drug demand driven by population growth and aging, alongside advancements in treatment technologies[30]. - Recent government policies, including the acceleration of innovative drug approvals and the establishment of stringent drug standards, are set to enhance the development of the pharmaceutical sector[31][32]. - The average price reductions from the eighth and ninth rounds of national centralized procurement were 56% and 58%, respectively, indicating a significant impact on pricing strategies within the industry[32]. - The company is positioned to benefit from the "High-Quality Development Action Plan for the Pharmaceutical Industry (2023-2025)" aimed at enhancing the resilience and modernization of the pharmaceutical sector[33]. Governance and Management - The board of directors consists of six members, including three independent directors, complying with legal requirements[78]. - The company maintains independent operations from its actual controller, ensuring no conflicts of interest or unfair related transactions[80]. - The company has established an independent financial department with a separate accounting system and tax obligations[82]. - The independent directors actively participate in training to stay informed about relevant laws and regulations[78]. - The company has a robust information disclosure system, ensuring timely and accurate communication with investors[78]. Environmental Compliance - The company adheres strictly to multiple environmental protection laws and regulations, ensuring compliance in its operations[115]. - The company reported no instances of exceeding pollution discharge standards in its operations[116]. - The company has implemented measures to ensure that all major pollutants are within regulatory limits, demonstrating commitment to environmental responsibility[116]. - Jiangsu Sihuan Bioengineering's wastewater treatment facility is subject to GB 21907-2008 standards, ensuring compliance with national regulations[119]. Legal and Regulatory Matters - The company faced a legal ruling in August 2023, with the court dismissing claims from three plaintiffs, resulting in a cost burden of ¥1,569,113[43]. - The company received a favorable court ruling in August 2023, dismissing a lawsuit with a claim amount of approximately 288.74 million yuan[131]. - There were no significant litigation or arbitration matters reported during the reporting period, with no expected liabilities arising from ongoing cases[137]. Shareholder Information - The largest shareholder, Yu Qinfeng, holds 14.32% of the shares, totaling 147,381,643 shares[165]. - The second largest shareholder, Wang Hongming, owns 14.00% of the shares, amounting to 144,138,394 shares[165]. - The company has a total of 104,201 ordinary shareholders at the end of the reporting period[164]. - The top ten shareholders include state-owned and private entities, with the largest private shareholder being Yu Qinfeng[165].

Financial Performance - The company's revenue for Q1 2024 was ¥56,398,850.85, a decrease of 1.08% compared to ¥57,013,482.58 in the same period last year[5] - The net loss attributable to shareholders was ¥2,967,209.29, an improvement of 84.35% from a loss of ¥18,959,108.45 in the previous year[5] - The basic and diluted earnings per share improved by 84.24%, from -¥0.0184 to -¥0.0029[5] - Net profit for the first quarter was a loss of ¥3,230,218.16, compared to a loss of ¥21,122,207.95 in the same period last year, representing an improvement of approximately 84.7%[19] - Operating profit improved to a loss of ¥4,048,302.24 from a loss of ¥21,889,366.63, indicating a significant reduction in losses[18] Cash Flow and Liquidity - The net cash flow from operating activities increased by 77.44% to ¥5,412,924.97, up from ¥3,050,580.73 in the same period last year[5] - Cash and cash equivalents at the end of Q1 2024 were CNY 16,499,359.61, down from CNY 18,927,001.92 at the beginning of the period, representing a decrease of 12.76%[13] - The cash and cash equivalents at the end of the period were ¥12,697,043.58, down from ¥25,137,867.09, indicating a decrease of approximately 49.5%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥653,491,489.39, a decrease of 1.13% from ¥660,975,034.49 at the end of the previous year[5] - Total liabilities decreased to CNY 143,941,215.12 from CNY 148,194,542.06, a reduction of 2.52%[15] - The company's total equity decreased to CNY 509,550,274.27 from CNY 512,780,492.43, a decline of 0.45%[15] - Non-current assets totaled CNY 147,465,828.09, down from CNY 151,595,031.95, a decrease of 2.73%[14] Expenses and Cost Management - The company reported a significant reduction in sales expenses by 50.38%, from ¥35,696,459.01 to ¥17,711,806.65[9] - Total operating costs decreased to ¥56,979,130.03 from ¥74,401,151.38, a reduction of approximately 23.4% year-over-year[18] - Research and development expenses were ¥6,903,522.01, slightly down from ¥7,340,182.16, reflecting a focus on cost management[18] Investment and Income - Investment income increased by 115.94%, from -¥218,024.90 to ¥34,744.67, indicating a turnaround in joint ventures[9] - The company reported an investment loss of ¥34,744.67, a significant recovery from a loss of ¥218,024.90 in the previous year[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 109,093, with the top ten shareholders holding significant stakes[10] Government Support - The company received government subsidies amounting to ¥37,368.06 during the reporting period[6] Other Information - The company has not reported any new product launches or significant market expansion strategies during this quarter[12] - The first quarter report has not been audited[24] - The new accounting standards will be implemented starting in 2024[23]

实际控制人陆克平先生持有公司股份 317,664,846 股，截止公告日，累计质 押股份数量 285,990,000 股，占其所持公司股份数量的 90.03%；累计被司法冻 结股份数量 18,725,100 股，占其所持公司股份数量的 5.89%，请投资者注意相 关风险。 根据中国证监会向江苏四环生物股份有限公司（以下简称"公司"）送达的 《行政处罚决定书》（【2020】17 号）所述，陆克平拥有陆宇、郁琴芬、孙现、 郁叙法、周军、张惠丰、徐瑞康、赵龙、许稚、陈建国、王洪明、孙一帆、江苏 德源纺织服饰有限公司等账户的控制权，且其与赵红、华樱、倪利锋、何斌存在 一致行动关系，构成一致行动人，不晚于 2014 年 5 月 23 日成为公司的实际控制 人（具体内容详见公司临 2020-22 号公告）。 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2024 - 0 8 号 江苏四环生物股份有限公司 关于实际控制人部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 公司于今 ...

江苏四环生物股份有限公司 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，公 告不存在虚假记载、误导性陈述或者重大遗漏。 一、投资者索赔案件基本情况 2020年4月，江苏四环生物股份有限公司（以下简称"公司"）因虚假陈述 被中国证监会作出行政处罚及市场禁入（详见公司临-2020-22号公告）。 股票代码：000518 股票简称：四环生物 公告编号：临-2024-10 号 关于涉及投资者索赔事项的进展公告 江苏四环生物股份有限公司 2024年4月23日 1 截至本公告日,公司共收到了南京市中级人民法院送达的54名投资者的诉讼 材料，原告以证券虚假陈述责任纠纷为由对公司提起民事诉讼，累计金额为 899.29万元。 上述案件中，已有22名投资者与公司达成了诉前或诉中调解，公司累计支付 调解款92.18万元。 二、其他尚未披露的诉讼仲裁事项 截至本公告日，公司无应披露而未披露的其他诉讼、仲裁事项。 三、本次公告的诉讼（仲裁）事项对公司本期利润或期后利润的可能影响 公司已于 2023 年度就上述部分投资者索赔诉讼事项计提了预计负债，公司 将根据诉讼进展情况进行相应的会计处理。 公司将积极跟进相关诉讼进展 ...

近日，晨薇生态园与如皋市绿四方园林绿化工程有限公司达成了执行和解， 对方向相关法院申请将晨薇生态园移出失信被执行人名单。经公司查询中国执行 信息公开网公示信息显示，晨薇生态园已被移出失信被执行人名单。 公司指定的信息披露媒体为《证券时报》、《证券日报》、《中国证券报》 和巨潮资讯网（www.cninfo.com.cn），有关公司信息均以上述指定媒体刊登的 信息为准，敬请广大投资者注意投资风险。 特此公告 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2024 - 0 9 号 江苏四环生物股份有限公司 关于子公司被移出失信被执行人名单的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 受诉讼事项影响，江苏四环生物股份有限公司（以下简称"公司"）全资子 公司江苏晨薇生态园科技有限公司（以下简称"晨薇生态园"）被列入失信被执 行人名单，具体内容详见公司于 2024 年 3 月 26 日在巨潮资讯网上披露的《江苏 四环生物股份有限公司关于子公司被纳入失信被执行人名单的公告》（公告编号： 临-2024-05 号）。 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2024 - 0 6 号 江苏四环生物股份有限公司 第十届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏 2024 年 4 月 17 日在本公司会议室以现场结合通讯的方式召开了第十届董事 会第四次会议。出席会议董事应到 6 名，实到 6 名，分别为郭煜、陆宇、文军、 刘卫、吴良卫、王莉。公司部分监事和高级管理人员列席本次会议。本次会议符 合《公司法》和《公司章程》有关规定，形成的决议合法、有效。 审议通过了关于聘任赵洁为公司财务总监的议案； 根据《深圳证券交易所股票上市规则》及《公司章程》等相关规定，经公司 董事长提名，公司董事会提名委员会和审计委员会审核通过，公司董事会同意聘 任赵洁女士为公司财务总监，任期自本次董事会审议通过之日起至第十届董事会 任期届满之日止。具体内容详见同日刊登于《中国证券报》、《证券时报》、《证 券日报》和巨潮资讯网（http://www.cninfo.com.cn）的《江苏四环生物股份有 限公司关于聘任财务总监的公 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2024 - 0 7 号 江苏四环生物股份有限公司 2024 年 4 月 17 日 1 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2024 - 0 7 号 赵洁：1994 年出生，无境外永久居留权，毕业于中国矿业大学徐海学院， 本科学历，主要工作经历：江阴金瑞织染有限公司财务负责人。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日召开 第十届董事会第四次会议，审议通过了《关于聘任赵洁为公司财务总监的议案》。 根据《深圳证券交易所股票上市规则》及《公司章程》等相关规定，经公司 董事长提名，公司董事会提名委员会和审计委员会审核通过，公司董事会同意聘 为赵洁女士为公司财务总监（简历请见附件），任期自本次董事会审议通过之日 起至第十届董事会任期届满之日止。 特此公告 江苏四环生物股份有限公司 关于聘任财务总监的公告 截至公告日，赵洁女士未 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2024 - 0 5 号 江苏四环生物股份有限公司 敬请广大投资者注意投资风险。 特此公告 江苏四环生物股份有限公司 2024 年 3 月 25 日 1 关于子公司被纳入失信被执行人名单的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）近日通过中国执行信息公 开网公示信息查询，获悉全资子公司江苏晨薇生态园科技有限公司（以下简称"晨 薇生态园"）被纳入失信被执行人名单，具体情况如下： 二、其他情况 上述事项暂未对公司正常生产经营产生重大不利影响,公司正积极与相关方 进行沟通，力争尽快妥善解决上述失信执行案件。同时，公司董事会将持续关注 相关事项的进展，及时履行信息披露义务。 被执行人 执行 法院 立案 时间 执行依据 文号 案号 生效法律文书确定的义务 概要 失信被执 行人行为 具体情形 江苏晨薇 生态园科 技有限公 司公司 昭通 市昭 阳区 人民 法院 2024 年 1 月 10 日 （2023） 云 06 民 终 ...

2024 年 3 月 8 日 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2024 - 0 4 号 江苏四环生物股份有限公司 关于补选公司第十届监事会职工代表监事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《公司法》及《公司章程》的有关规定，江苏四环生物股份有限公司于 2024 年 3 月 8 日召开了 2024 年第一次职工代表大会，审议通过了《关于补选公 司第十届监事会职工代表监事的议案》，选举华璟轩（简历附后）为公司第十届 监事会职工代表监事,任期至第十届监事会换届之日止。 特此公告 江苏四环生物股份有限公司 1 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： 四 环 生 物 公告编号：临 - 2024 - 0 4 号 华璟轩，1997 年 6 月出生，本科学历，园林专业,曾担任江苏新思维设计工 程有限公司资料员,目前在江苏晨薇生态园科技有限公司任园林设计工作。 华璟轩先生未持有公司股份；与公司其他董事、监事、高级管理人员及持有 公司 5%以上股份的股东、实际控制人之间 ...